GrayMatters Health

Meet Amir A.Qadir, Ph.D, MBA, Product Manager at GMH! With a PhD in Biomedical Engineering and an MBA, Amir joined the GMH team after working in neuroscience tech, particularly focusing on Parkinson’s disease. Amir is passionate about improving mental health care by bringing attention to "invisible injuries" and providing meaningful solutions. In his role, Amir oversees the seamless collaboration across departments, balancing regulatory requirements with product design to address the needs of both patients and clinicians. Amir uses creative problem-solving to ensure our products are not only innovative but also practical and compliant. Outside of work, Amir enjoys spending quality time with his family, especially since the arrival of his first child.

The end of treatment doesn't have to mark the end of progress. With Prism for PTSD?, many patients continue to experience positive effects after completing treatment and three months later. By applying the mental strategy practiced in the clinic into their daily life, Prism empowers your patients with a new skill for effective PTSD management. Think durability, think Prism. https://lnkd.in/dqWTUG97

Distressing memories and nightmares are among the most persistent and debilitating symptoms of PTSD, often impacting daily functioning and quality of life. In previous studies, Prism for PTSD? showed significant improvement in reducing these symptoms, with progress observed at 3-month follow-up. This data highlights the potential of Prism for PTSD as a valuable adjunctive therapy in the management of PTSD. https://lnkd.in/dqWTUG97

Prism for PTSD? is ISO 27001 certified, ensuring the highest international standards in protecting the security and privacy of customer data.

Our CCO,?Kirk Thelander,?and Product and Program Director,?Yuval Eden ??,?made it through the snowstorm in Colorado to attend the 2024 Neuroscience Education Institute Congress. There were many interesting sessions on new approaches for treating mental health disorders. A highlight was the presentation, "Safe and Sound: Improving Outcomes for Patients with PTSD," with William Sauve MD, expressing his excitement for Prism for PTSD?.

GrayMatters Health is proud to be a bronze sponsor of the 2024 Technology in Psychiatry Summit, hosted by esteemed institutions Harvard Medical School, Mass General Brigham, and the Institute for Technology in Psychiatry at McLean Hospital! On December 7, this premier event will unite global experts to explore the latest advancements in digital health and technology in psychiatry. Together, we'll address the ethical, policy, and regulatory challenges shaping the future of mental health care. Learn more: https://lnkd.in/dyB8MXV6

Although first-line treatment for post-traumatic stress disorder (PTSD) is psychotherapy, it is estimated that up to half 50% of patients do not respond to treatment. What if there was a tool that could augment standard of care outcomes? Prism for PTSD? offers a clinician-directed, personalized treatment option for patients. An engaging software and amygdala-based biomarker work together with EEG to help patients learn to regulate their PTSD symptoms. Clinical studies have demonstrated only mild side effects, such as fatigue, that self-resolved after the Prism session with no further intervention. Whether you are a psychiatrist in a private practice or a hospital setting, explore how prescribing Prism can enhance your clinical toolkit, easily fit into your practice, and help make a measurable impact on your patients' recovery. https://lnkd.in/dm_kzWiH

Honoring veterans and their families, in active duty or who have fallen, for their commitment to freedom.

We’re thrilled to share that The Institute for Advanced Psychiatry in Fort Worth, Texas, is now offering their patients treatment with Prism, our FDA-cleared self-neuromodulation device for PTSD. Dr. Diana Ghelber psychiatrist at Institute for Advanced Psychiatry said, “Prism is a powerful intervention on the leading edge of PTSD treatment. We are placing the power to heal directly in the patient’s hands without requiring them to re-experience trauma.”

GMH Chief Medical Scientist Prof. Talma Hendler was on the stage at the Real-Time Functional Imaging and Neurofeedback meeting | rtFIN 2024 in Heidelberg, Germany together with scientists from around the world. Prof Hendler shared insights on how scientific findings were translated into an FDA-cleared self-neuromodulation device for treating PTSD. ? Curious about Prism's journey from the research lab to treating patients in the clinic? Learn more here: https://lnkd.in/dGxV2hRy Rani Cohen | Oded Kraft